{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:09:14Z","timestamp":1773356954954,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clinthera.2014.06.007","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T21:00:39Z","timestamp":1404334839000},"page":"1147-1158","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetic Interaction Between Rosuvastatin and Telmisartan in Healthy Korean Male Volunteers: A Randomized, Open-label, Two-period, Crossover, Multiple-dose Study"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01992601","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mijeong","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyerang","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankil","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinju","family":"Guk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Bok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Youn","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.06.007_bib1","unstructured":"The results of 2011 death cause statistics survey. Korea National Statistical Office, 2012. http:\/\/kostat.go.kr\/portal\/korea\/kor_nw\/2\/6\/2\/index.board?bmode=read&aSeq=260046. Accessed February 20, 2014."},{"key":"10.1016\/j.clinthera.2014.06.007_bib2","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics--2013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.06.007_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11906-006-0028-5","article-title":"Management of hypertension and dyslipidemia","volume":"8","author":"Ferdinand","year":"2006","journal-title":"Curr Hyperten Rep"},{"key":"10.1016\/j.clinthera.2014.06.007_bib4","first-page":"926","article-title":"Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease","volume":"10","author":"Johnson","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2014.06.007_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(05)17833-7","article-title":"Treatment with drugs to lower blood pressure and blood cholesterol based on an individual\u2019s absolute cardiovascular risk","volume":"365","author":"Jackson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.06.007_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/VHRM.S3662","article-title":"Efficacy and safety of rosuvastatin in the management of dyslipidemia","volume":"5","author":"Rubba","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2014.06.007_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","article-title":"Telmisartan: a review of its use in the management of hypertension","volume":"66","author":"Battershill","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.06.007_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2010.03.018","article-title":"Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study","volume":"32","author":"Rizos","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.007_bib9","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1111\/j.1755-5922.2011.00290.x","article-title":"The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins","volume":"30","author":"Hua","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2014.06.007_bib10","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.clinthera.2014.06.007_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/clpt.2012.79","article-title":"A perspective on efflux transport proteins in the liver","volume":"92","author":"Kock","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.06.007_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2014.06.007_bib13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.clinthera.2014.06.007_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cca.2008.09.020","article-title":"Telmisartan pharmacokinetics in Japanese renal transplant recipients","volume":"399","author":"Miura","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clinthera.2014.06.007_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1124\/dmd.107.018903","article-title":"Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide","volume":"36","author":"Ishiguro","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.007_bib16","unstructured":"MICARDIS\u00ae (telmisartan) Tablets - HIGHLIGHTS OF PRESCRIBING INFORMATION http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Micardis+Tabs\/MICARDIS20-40-80mg.PDF. Accessed February 20, 2014"},{"key":"10.1016\/j.clinthera.2014.06.007_bib17","unstructured":"GUIDELINE FOR KOREAN GOOD CLINICAL PRACTICE. http:\/\/www.gcphelpdesk.com\/knowledge-base\/item\/download\/43. Accessed June 26, 2014."},{"key":"10.1016\/j.clinthera.2014.06.007_bib18","unstructured":"Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/. Accessed June 26, 2014"},{"key":"10.1016\/j.clinthera.2014.06.007_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpba.2006.12.022","article-title":"Quantitative determination of rosuvastatin in human plasma by ion pair liquid-liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry","volume":"44","author":"Lan","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2014.06.007_bib20","first-page":"289","article-title":"Estimation of Telmisartan in Human Plasma by Reversed Phase Liquid Chromatography Coupled with Tandem Mass Spectrometry - A Bioequivalence Study Application","volume":"3","author":"Terish","year":"2011","journal-title":"Der Pharmacia Lettre"},{"key":"10.1016\/j.clinthera.2014.06.007_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17425255.2011.538383","article-title":"The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins","volume":"7","author":"Hu","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2014.06.007_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/dmd.112.049452","article-title":"Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans","volume":"41","author":"Zhang","year":"2013","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.clinthera.2014.06.007_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm Drug Disp"},{"key":"10.1016\/j.clinthera.2014.06.007_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson SG1","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.06.007_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/Drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers","volume":"47","author":"Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clinthera.2014.06.007_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0091270006297225","article-title":"Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension","volume":"47","author":"Bajcetic","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.007_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/00005344-200111000-00004","article-title":"Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge","volume":"38","author":"Stangier","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.007_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/aps.2010.169","article-title":"Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients","volume":"32","author":"Yang","year":"2011","journal-title":"Acta Pharmacol Sinica"},{"key":"10.1016\/j.clinthera.2014.06.007_bib29","unstructured":"CRESTOR\u00ae (rosuvastatin calcium) tablets - HIGHLIGHTS OF PRESCRIBING INFORMATION http:\/\/www1.astrazeneca-us.com\/pi\/crestor.pdf. Accessed April 27, 2014"},{"key":"10.1016\/j.clinthera.2014.06.007_bib30","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research, Guidance for Industry: Drug Interaction Studies \u2014 Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, 2012. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf Accessed April 27, 2014."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400366X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400366X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T19:25:59Z","timestamp":1538421959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181400366X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S014929181400366X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}